Project Grant R44AG094397
Award Date 9/20/25
Completion Date 8/19/28
Dollars Obligated $871K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Institute on Aging (NIA), through the Aging Research Federal Grant Program (CFDA 93.866), awarded a $500,000 Project Grant to T-Neuro Inc. to confirm the use of aberrant T cells as an amyloid-independent blood biomarker for potentially earlier diagnosis and tracking the progression of Alzheimer's disease (AD). The award period is from August 1, 2025 to July 31, 2026. The project aims to demonstrate that alterations in age-related cytolytic (CD8) T cells can impact AD pathology...
- This Project Grant award of $497,878 from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) will fund a Phase 0 study to evaluate the in vivo characteristics of a myeloperoxidase (MPO)-targeting PET imaging agent (18F-EH301) in healthy volunteers and early Alzheimer's disease (AD) patients. The study aims to develop a PET imaging tool that can detect and track neuroinflammation, a key early event in the development of AD, by specifically targeting...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $455,009 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop a novel [18F]-labeled amphiphilic PET probe that can cross the blood-brain barrier and track CD206+ microglia/macrophages in Alzheimer's disease. The goal is to create a non-invasive imaging method to detect anti-inflammatory M2-like microglia and macrophages, which play a key role in...
- The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded Aivocode, Inc. a $1,244,775 project grant to develop single domain antibodies targeting Connective Tissue Growth Factor (CTGF) for improving vascular dysfunction in Alzheimer's disease. The award period runs from September 2025 to May 2027. The funding will support preclinical research to test these single domain antibodies in mouse models of Alzheimer's disease, with the goal of...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel "theranostic" (therapeutic and diagnostic) Chimeric Antigen Receptor (CAR) T cell platform to detect and target senescent cells associated with Alzheimer's disease and other age-related disorders. The $834,627 award, made on March 19, 2025, supports the University of Florida's research to create unique probes and a signal-sensing chemically-induced proximity...
- The National Institute on Aging (NIA) awarded a $483,346 Project Grant to Meganano Diagnostics Inc. under the Aging Research Federal Grant Program (CFDA 93.866) for the development of an RT-qPCR assay for early diagnosis of Alzheimer's disease (AD). The project aims to leverage changes in T cell receptor (TCR) clonality in peripheral blood mononuclear cells (PBMCs) as a potential biomarker for early AD detection. Preliminary research by Meganano Diagnostics has demonstrated increased TCR...